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Introduction
Breast cancer is the most common form of cancer in
women from developed countries. Axillary lymph node
status is widely accepted as an important parameter for
assessing prognosis in breast cancer patients. However,
recurrence and death also occur in patients with node-
negative breast cancer (NNBC). A recurrence rate of 30%
may be expected during the first 5 years after diagnosis.
Prognostic factors such as tumour size, tumour grading,
hormone receptor status, age, histology, ploidy and prolif-
eration index are used to define subgroups of high-risk
NNBC patients [1–8]. Despite the availability of these
prognostic markers, high-risk NNBC patients cannot be
identified with sufficient accuracy. This has led to a search
for new and possibly stronger prognostic markers in order
to define new subgroups and to facilitate decision-making
with respect to appropriate therapy [2,3,9].
AGCN = average gene copy number; CART = Classification and Regression Trees; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; DFS =
disease-free survival; NNBC = node-negative breast cancer; FEC = fluorouracil, epirubicin, cyclophosphamide; OS = overall survival; PCR = poly-
merase chain reaction.
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Abstract
Background: At present, node-negative, high-risk breast
cancer patients cannot be identified with sufficient accuracy.
Consequently, further strong prognostic factors are needed.
Methods: Among 181 node-negative breast cancer (NNBC)
patients, c-myc and  HER-2/neu oncogenes were identified
prospectively using double differential PCR. The possible
impact of amplification of those oncogenes on disease-free
survival (DFS) and overall survival was examined. Furthermore,
the possible effects of adjuvant therapies on rate of recurrence
and mortality in oncogene-amplified NNBC patients were
investigated.
Results: The prevalence rates for amplification of c-myc and
HER-2/neu were 21.5% and 30.4%, respectively. On
univariate analysis, c-myc-amplified NNBCs were associated
with significantly shorter DFS at 36 months after the initial
diagnosis (85.3% versus 97.3%). As compared with
nonamplified cancers, HER-2/neu-amplified NNBCs did not
exhibit any significant differences after 36 months and
95 months. Multivariate analysis indicated that c-myc
amplification and tumour size, in contrast to HER-2/neu
amplification, oestrogen receptor status, grading and age, were
the only independent parameters for DFS. During the period of
observation, we found no evidence for an impact of
amplification of the oncogenes on overall survival in all cases.
With respect to various adjuvant systemic therapies such as
chemotherapy (cyclophosphamide, methotrexate, 5-
fluorouracil; fluorouracil, epirubicin, cyclophosphamide) and
endocrine therapy (tamoxifen), no significant differences were
identified in oncogene-amplified NNBC patients in terms of
DFS and overall survival. However, those c-myc-amplified
NNBC patients who did not receive adjuvant systemic therapy
exhibited significantly shorter DFS and overall survival as
compared with c-myc-nonamplified patients.
Conclusion: C-myc amplification appears to be a strong
prognostic marker with which to predict early recurrence in
NNBC patients. C-myc-amplified NNBC patients without adjuvant
systemic therapy experienced shorter DFS and overall survival.
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Numerous reports have described the correlation between
amplification of oncogenes and its impact on the course of
breast cancer disease [4–7,10–32]. In a meta-analysis in
which 29 studies were evaluated [33], c-myc amplification
exhibited significant but weak associations with tumour
grade, lymph node metastasis, negative progesterone
receptor status and postmenopausal status. Furthermore
c-myc amplification was significantly associated with risk
for recurrence and death. However, studies in recent
years have further shown that the c-myc gene participates
in most aspects of cellular function, including replication,
growth, metabolism, differentiation and apoptosis [34].
Amplification of the oncogene HER-2/neu has also been
shown to be indicative of poor prognosis in breast cancer.
Studies revealed that the prognostic effect of HER-2/neu
is stronger for survival than for recurrence [16,19,20,22,
27,29]. Furthermore, increased HER-2/neu levels in
primary tumours were associated with a poor response to
endocrine therapy [5,12,15,32].
A drawback of many studies of oncogenes in human
breast cancer is that usually only one oncogene was eval-
uated. Based on a series of unselected cases, in the
present study we examined the possible influence of the
amplification of the oncogenes c-myc and HER-2/neu on
disease-free survival (DFS) and overall survival (OS).
Furthermore we studied whether adjuvant therapies such
as chemotherapy and endocrine treatment or no treatment
at all had any impact on DFS and OS among oncogene-
amplified NNBC patients [1–3,8,9,32,35–38].
Patients and methods
Among 181 NNBC patients who had undergone breast-
conserving therapy or modified mastectomy combined
with axillary lymphadenectomy of level 1 and 2 (at least 10
lymph nodes per patient had been removed), c-myc and
HER-2/neu oncogenes were assessed prospectively
using double differential PCR.
Table 1 shows some clinical, histological and molecular
parameters. The median follow-up period was 42 months.
Postoperatively, the following therapies were administered
in addition to radiotherapy: tamoxifen 20 mg/day for
5 years in 54.7% of patients; and chemotherapy (six cycles
of cyclophosphamide, methotrexate, 5-fluorouracil [CMF]
or four cycles of fluorouracil, epirubicin, cyclophosphamide
[FEC]) in 33.7% of patients. Of the NNBC patients, 11.6%
did not receive any further systemic therapy.
After tissue preparation, malignant and normal tissues
were kept fresh and transported to the pathologist (U.B.).
The pathologist dissected samples for assessment of
oncogenes and hormone receptors. A positive receptor
status was defined as the presence of more than 10
fmol/mg cytosol protein. The histopathological grading
was performed according to the method of Bloom and
Richardson [39]. Lymph node sections were stained with
haemotoxylin and eosin; immunohistochemical investiga-
tions were not performed. The tumour tissues were stored
at –70°C and the DNA was isolated using the Fast Prep
System (Bio 101 Savant, Savant Instruments, Inc., Hol-
brook, NY, USA). Less than 200 mg (10–200 mg) tissue
was homogenized using FastDNA Kit in the Fast Prep
Machine. After preparing the DNA, the content was mea-
sured and the isolated DNA was stored at –20°C. General
details for the double differential PCR technique, repro-
ducibility and clinical significance were described previ-
ously [17,18,28,40]. A cutoff point of more than
2.0 average gene copy number (AGCN) was considered
to be positive for HER-2/neu amplification [40]. To calcu-
Table 1
Clinical, histological and molecular parameters of 181 node-
negative breast cancer patients
Parameter Number of patients (%)
Tumour size
T1 118 (65.2)
T2 54 (29.8)
T3/4 9 (5.0)
Age (years)
<40 14 (7.7)
40–55 46 (25.4)
>55 121 (66.9)
Histopathological grading
G1 5 (2.8)
G2 105 (58)
G3 71 (39.2)
ER status
ER negative 64 (35.4)
ER positive 115 (63.5)
Unknown 2 (1.1)
PR status
PR negative 66 (36.5)
PR positive 112 (61.9)
Unknown 3 (1.7)
Oncogenes
C-myc nonamplified 142 (78.5)
C-myc amplified 39 (21.5)
HER-2/neu nonamplified 126 (69.6)
HER-2/neu amplified 55 (30.4)
C-myc and HER-2/neu coamplified 22 (12.2)
ER, oestrogen receptor; PR, progesterone receptor.Breast Cancer Research    Vol 5 No 2 Schlotter et al.
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late the cutoff point for c-myc amplification, all NNBC
patients were subjected to Classification and Regression
Trees (CART) analysis. A cutoff value of 2.1 AGCN for c-
myc oncogene led to the best distinction between
patients. Fig. 1 shows the CART analysis for all c-myc
values [41].
Results were evaluated using the SPSS system (SPSS
GmbH Software, Munich, Germany). The monoparametric
survival curves were determined using the Kaplan–Meier
method in order to estimate the impacts of intratumoural
c-myc and  HER-2/neu oncogene amplification on DFS
and OS. Statistical deviations were defined using the log-
rank test. Recurrence of disease was found at the follow-
ing locations: local (n = 2), contralateral (n = 1), axilla
(n = 2), lung (n = 1), brain (n = 1), liver (n = 1) and skin
(n = 1). During the period of observation, 14 patients died.
In order to derive relevant information regarding the
effects of oncogene amplification on the course of breast
cancer disease, the accumulated values were determined
after postoperative periods of 36 and 95 months. We
applied the multivariate Cox model to enable us to identify
independently predictive parameters [42]. Parameters
considered included the oncogenes c-myc and  HER-
2/neu, tumour size, histopathological grading, oestrogen
receptor status and age (<40 or ≥40 years).  P < 0.05
was considered statistically significant.
Results
The prevalence rates for amplification of c-myc and HER-
2/neu were 21.5% and 30.4%, respectively. Coamplifica-
tion was found in 22 patients (12.2%; Table 1). Among
those patients with c-myc amplification five recurrences
were identified (5/39 [12.8%]), and among those with
HER-2/neu amplification two recurrences (2/55 [3.6%])
were identified. Among those patients in whom neither c-
myc nor HER-2/neu were amplified four recurrences were
found (4/109 [3.6%]), and among those with coamplifica-
tion of both oncogenes two recurrences (2/22 [9.1%])
were observed. Four patients with c-myc amplification
(4/39 [10.3%]) and three patients with HER-2/neu ampli-
fication (3/55 [5.5%]) died. Nine patients who lacked
amplification of either oncogene (9/109 [8.3%]) and two
patients with coamplification (2/22 [9.1%]) died.
Using univariate analysis, c-myc-amplified cancers were
associated with a significantly lower DFS of 85.3%, as
compared with 97.3% (P = 0.0290) among c-myc-non-
amplified breast cancers. Ninety-five months after diagno-
sis (operation), the estimated DFS of c-myc-amplified
cancer patients was only 85.3%, as compared with
95.6% among c-myc-nonamplified patients (P = 0.0079).
Comparison of nonamplified cancers with HER-2/neu-
amplified cancers did not reveal any significant differences
with regard to DFS (Fig. 2).
Multivariate analysis revealed that c-myc amplification and
tumour size, in contrast to oestrogen receptor status,
grading and age, were the only independent parameters
impacting on DFS (Table 2). With regard to OS, no inde-
pendent parameters were identified among the prognostic
markers referred to above.
Figure 1
Classification and Regression Trees (CART) analysis of c-myc among
181 node-negative breast cancer patients. dd, double differential.
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Figure 2
Kaplan–Meier estimation of disease-free survival (DFS) among 181
node-negative breast cancer patients.
100 80 60 40 20 0
1.00
0.9
0.8
0.7
0.6
0.5
Time (months)
Time (months)
c-myc nonamplified
c-myc amplified
P = 0.0079
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
D
F
S
 
(
%
)
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
D
F
S
 
(
%
)
HER-2/neu nonamplified
HER-2/neu amplified
P = 0.5868
100 80 60 40 20 0
1.00
0.9
0.8
0.7
0.6
0.5Regarding various adjuvant systemic therapies, such as
chemotherapy (CMF, FEC) and endocrine therapy (tamox-
ifen), no significant differences were observed with
respect to DFS and OS in c-myc-amplified and HER-2/
neu-amplified NNBC patients in comparison with non-
amplified patients. However, significantly shorter DFS and
OS were observed among c-myc-amplified patients who
did not receive systemic adjuvant therapy. No correspond-
ing associations were found among HER-2/neu-amplified
NNBC patients as compared with nonamplified patients
(Tables 3 and 4).
Discussion
Numerous clinical studies have proved axillary lymph node
status to be the dominant factor for prognosis and predic-
tion of DFS and OS in breast cancer patients. The fact of
the matter is that even among NNBC patients 25–30%
can be expected to progress or even die. The advantage
Available online http://breast-cancer-research.com/content/5/2/R30
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Table 2
Tumour parameters and disease-free survival in 181 node-negative breast cancer patients in univariate and multivariate analyses
DFS after 36 months DFS after 95 months
Parameter Univariate P value Multivariate P value Univariate P value Multivariate P value
Tumour size 0.0223* 0.024* 0.0047* 0.002*
c-myc 0.0290* 0.013* 0.0079* 0.004*
HER-2/neu 0.2943 0.252 0.5868 0.166
Oestrogen receptor 0.6797 0.192 0.5363 0.622
Tumour grade 0.0998 0.128 0.0255* 0.663
Age < 40, ≥40 0.2330 0.965 0.0920 0.717
*P < 0.05.
Table 3
Recurrences and disease-free survival in 181 node-negative
breast cancer patients after different adjuvant systemic
therapies or no therapy
Recurrence 
Subgroup n (n [%]) DFS (P)
Chemotherapy (n = 61)
c-myc Amplified 19 3 (15.8) 0.1748
Nonamplified 42 2 (4.8)
HER-2/neu Amplified 26 1 (3.8) 0.2552
Nonamplified 35 4 (11.4)
Endocrine therapy (n = 99)
c-myc Amplified 15 1 (6.7) 0.3325
Nonamplified 84 2 (2.4)
HER-2/neu Amplified 22 1 (4.5) 0.6641
Nonamplified 77 2 (2.6)
No therapy (n = 21)
c-myc Amplified 5 1 (20.0) 0.0209*
Nonamplified 16 0 (0)
HER-2/neu Amplified 7 0 (0) 0.4969
Nonamplified 14 1 (7.1)
*P < 0.05 (log-rank test). DFS, disease-free survival.
Table 4
Mortality and overall survival in 181 node-negative breast
cancer patients after different adjuvant systemic therapies or
no therapy
Mortality 
Subgroup n (n [%]) OS (P)
Chemotherapy (n = 61)
c-myc Amplified 19 1 (5.3) 0.7442
Nonamplified 42 3 (7.1)
HER-2/neu Amplified 26 0 (0.0) 0.1042
Nonamplified 35 4 (11.4)
Endocrine therapy (n = 99)
c-myc Amplified 15 1 (6.7) 0.9846
Nonamplified 84 6 (7.1)
HER-2/neu Amplified 22 2 (9.1) 0.8307
Nonamplified 77 5 (6.5)
No therapy (n = 21)
c-myc Amplified 5 2 (40.0) 0.0098*
Nonamplified 16 1 (6.3)
HER-2/neu Amplified 7 1 (14.3) 0.5649
Nonamplified 14 2 (14.3)
*P < 0.05 (log-rank test). OS, overall survival.conferred by adjuvant chemotherapy or endocrine therapy
was examined in randomized studies [2,3,8,9,35–38].
Because adjuvant therapies may positively impact on
outcome in only around 15%, the costs of these therapies
make their routine application in all NNBC patients inap-
propriate [1]. For this reason, predictive factors that accu-
rately define subgroups of NNBC patients who may
benefit from adjuvant systemic therapy would be a great
advantage.
In the present study the oncogenes c-myc and HER-2/
neu were examined with regard to their ability to predict
DFS, OS and rate of recurrence, as well as mortality. All
patients were randomly selected from one department
(Frauenklinik Klinikum Ibbenbueren, Ibbenbueren,
Germany). C-myc amplification was identified in 21.5%
and  HER-2/neu amplification in 30.4%. Berns and
coworkers [12–14] reported amplification of c-myc in
20% and of HER-2/neu in 24% using a standard southern
blot technique. In a selected high-risk cohort of NNBC
patients, Roux-Dosseto et al. [26] applied the same
method and found prevalence rates for c-myc and HER-2/
neu amplification of 25% and 31%, respectively. Those
oncogenes were assessed in the present study using a
double differential PCR technique [17,18,40,43]. Using
this method, Brandt et al. [17] found c-myc to be amplified
in 19.7% and HER-2/neu in 16.7% of breast cancers,
without consideration of nodal status; coamplification of
those oncogenes was present in 7%. In the present study,
simultaneous amplification of both oncogenes was
observed in 12.2%. As in the present investigation, Roux-
Dosseto et al. [26] found that c-myc amplification among
NNBC patients was significantly associated with earlier
recurrence in univariate and multivariate analyses.
However,  HER-2/neu-amplified NNBC patients did not
have the same outcome. Accordingly, c-myc amplification
appears to be an independent prognostic marker, which
has greater predictive power than does oestrogen recep-
tor status and tumour grade. As early as 1992, Berns and
coworkers [11,12,14] reported that patients with c-myc-
amplified breast cancers had an unfavourable prognosis.
The first study to mention possible prognostic importance
of HER-2/neu gene amplification was reported in 1987 by
Slamon et al. [27]. That study included 187 patients with
NNBC and node-positive breast cancer; by univariate and
multivariate analyses, it revealed that HER-2/neu amplifi-
cation correlated very closely with shorter DFS and OS in
a subgroup of 87 node-positive patients. In 1993, in an
analysis of 210 patients, Press et al. [7] found that amplifi-
cation of HER-2/neu correlated with unfavourable progno-
sis with respect to DFS.
Attempts by other investigators to confirm these findings
were met with various degrees of success. Some studies
claimed that HER-2/neu status was an independent pre-
dictive factor in the case of breast cancer, whereas other
studies could not confirm this [6,14,16,19,29,30]. It is
certainly of great interest to the clinician that only two out
of five studies including more than 100 patients and with a
follow-up period of at least 3 years attributed some prog-
nostic value to HER-2/neu amplification among patients
with NNBC [6,7,16,19,28]. Almost all of the studies that
dealt with HER-2/neu status and DFS, as well as OS,
showed no benefit of this oncogene in the prognosis of
NNBC patients. In a survey conducted by Ravdin and
Chamness [24], only one [22] of 11 studies concerning
immunohistochemical overexpression of HER-2/neu indi-
cated a significant result with respect to OS in multivariate
analysis.
In the present study, 19 out of 39 c-myc-amplified patients
received chemotherapy, 15 patients received endocrine
therapy and five patients received no further therapy. The
greatest recurrence rates were noted in the group of
patients who received no therapy (20%) and in those who
received chemotherapy (16%). The lowest recurrence rate
of 7% was seen in patients treated with tamoxifen. All
patients who received endocrine therapy (n = 99) were
characterized by positive oestrogen and/or progesterone
receptor status. The proto-oncogene c-myc can be upreg-
ulated by oestrogen stimulation of hormone-dependent
breast cancer cells. Endocrine therapy with the antioestro-
gen tamoxifen can mediate the downregulation of c-myc,
culminating in cell cycle arrest [44]. Berns et al. [12]
reported that 38% of patients with amplification of c-myc
or with coamplification of c-myc and HER-2/neu profited
from endocrine therapy. C-myc-amplified patients affected
by metastatic disease showed a tendency toward longer
DFS with endocrine therapy, as compared with shorter
DFS following second-line chemotherapy. However, the
minor rate of response after chemotherapy did not corre-
late with OS. The poorer responses to chemotherapy
among patients with c-myc-amplified tumours in the
present study (recurrence rate 16%) may be in agreement
with experimental findings in erythroleukaemia cells that
the degree of cis-platinum resistance correlated directly
with the level of c-myc expression [45].
In the present study, 26 out of 55 HER-2/neu-amplified
patients received chemotherapy, 22 patients received
endocrine therapy and seven patients received no further
therapy. In total, low recurrence rates of 3.8%, 4.5% and
0% were found in the above-mentioned therapy groups,
respectively (Table 3). Compared with nonamplified
patients administered the same therapies, no significant
differences with regard to DFS and OS were observed. In
contrast to that finding, c-myc-amplified patients not
administered adjuvant systemic therapy exhibited a signifi-
cantly shorter DFS and OS than did nonamplified patients
who also received no adjuvant systemic therapy. However,
the therapy groups analyzed in the present study are
Breast Cancer Research    Vol 5 No 2 Schlotter et al.
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of the findings.
Higher recurrence rates or poor response to endocrine
treatment with tamoxifen in patients with HER-2/neu-
amplified hormone receptor positive tumours, as reported
in studies in node-positive or metastatic breast cancer
[12,15,32], were not observed in the present study.
Although deregulated HER-2/neu activity can strongly
stimulate cytoplasmic signalling pathways, which in turn
impinge on c-myc at multiple levels causing its deregu-
lated expression [46], this scenario does not appear to be
active in NNBC because the recurrence rate of 22 c-myc
and  HER-2/neu coamplified patients was only 9%.
However, among those patients in whom coamplification
of c-myc and HER-2/neu was absent the recurrence rate
was lower (4/109 [3.6%]). Differences in the numbers of
recurrences and deaths can be accounted for by the fact
that some deaths were not related to tumours.
Conclusion
C-myc amplification appears to represent a prognostic
marker with which early recurrence may be predicted in
NNBC patients. C-myc-amplified NNBC patients who
were not administered adjuvant systemic therapy suffer
shorter DFS and OS. C-myc could be used together with
the tumour-associated protease urokinase-plasminogen
activator and its inhibitor (i.e. plasminogen activator
inhibitor-1), after further randomized studies have been
conducted, to confirm whether NNBC patients should
receive adjuvant systemic therapy [47–49].
Competing interests
None declared.
References
1. McGuire W: Adjuvant therapy of node-negative breast cancer.
N Engl J Med 1989, 320:525-527.
2. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D,
Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et
al.:  A randomized clinical trial evaluating tamoxifen in the
treatment of patients with node- negative breast cancer who
have estrogen-receptor-positive tumors. N Engl J Med 1989,
320:479-489.
3. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S,
Wickerman DL, Wolmark N, Fisher ER, Margolese R, Sutherland C,
et al.:  A randomized clinical trial evaluating sequential
methotrexate and fluorouracil in the treatment of patients with
node-negative breast cancer. N Engl J Med 1989, 320: 473-478.
4. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne
CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire W:
HER-2/neu in node-negative breast cancer: prognostic signif-
icance of overexpression influenced by the presence of in situ
carcinoma. J Clin Oncol 1992, 10:599-605.
5. Nicholson S, Wright S, Sainsbury JRC, Halcrow P, Kelly P, Angus
B, Farndon JR, Harns AL: Epidermal growth factor receptor
(EGFR) as a marker for poor prognosis in node-negative
breast cancer patients: neu and tamoxifen failure. J Steroid
Biochem Mol Biol 1990, 27:811-815.
6. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW,
Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon
DJ, Fourney RM: Correlation between c-erb B-2 amplification
and risk of recurrent disease in node-negative breast cancer.
Cancer Res 1991, 51:4960-4970.
7. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M,
Danyluk J, Godolphin W, Sliwowski M, Akita R, Paterson MC,
Slamon DJ: Her-2/neu expression in node-negative breast
cancer: direct tissue quantitation by computerized image
analysis and association of overexpression with increased
risk of recurrent disease. Cancer Res 1993, 53:4960-4970.
8. The Ludwig Breast Cancer Study Group: Prolonged disease-
free survival after one course of perioperative adjuvant
chemotherapy for node-negative breast cancer. N Engl J Med
1989, 320:491-495.
9. Fisher B, Slack N, Katrych D, Wolmark N: Ten years follow up
results of patients with carcinoma of the breast in a co-opera-
tive clinical trial evaluating surgical adjuvant chemotherapy.
Surg Gynecol Obstet 1975, 140:528-534.
10. Ali IU, Campbell G, Lidereau R, Callahan R: Lack of evidence for
the prognostic significance of c-erb B-2 amplification. Onco-
gene Res 1988, 3:139-146.
11. Berns PMJJ, Foekens JA, Van Putten WLJ, Van Staveren IL, Alex-
ieva-Figusch J and Klijn JGM: Prognostic factors in human
primary breast cancer: comparison of c-myc and HER2/neu
amplification. J Steroid Biochem Mol Biol 1992, 43:13-19.
12. Berns, PMJJ, Foekens JA, Van Staveren IL, Van Putten WLJ, De
Koning HYWCM, Portengen Hm Klijn JGM: Oncogene amplifi-
cation and prognosis in breast cancer: relationship with sys-
temic treatment. Gene 1995, 159:11-18.
13. Berns PMJJ, Foekens JA, Van Putten WLJ, Van Staveren IL, Alex-
ieva-Figusch J, Klijn JGM: Prognostic factors in human primary
breast cancer: comparison of c-myc and HER2/neu amplifica-
tion. J Steroid Biochem Mol Biol 1992, 43:13-19.
14. Berns PMJJ, Klijn JGM, Van Putten WLJ, Van Staveren IL, Porten-
gen H, Foekens JA: c-myc amplification is a better prognostic
factor than HER2/neu amplification in primary breast cancer.
Cancer Res 1992, 52:1107-1113.
15. Bianco AR, Laurentils MD, Carlomagno C, Lauria R, Petrella G,
Panico L, Pettinato G, Perrone F, Gallo C, Marinelli A, Placido SD:
20 year update of the Naples Gun trial of adjuvant breast
cancer therapy: evidence of interaction between c-erb B-2
expression and tamoxifen efficacy [meeting abstract]. In Pro-
ceedings of the American Society of Clinical Oncology 34th
Annual Meeting, May 16–19, 1998. Los Angeles, CA:373.
16. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua
SA, Killander D, McGuire WL: c-erb B-2 amplification predicts
poor survival in node-positive breast cancer. Cancer Res
1990, 50:4332-4337.
17. Brandt B, Vogt U, Assmann G: Prognostische Relevanz der
Amplifikation der Onkogene c-erb B-2 und c-myc beim Mam-
makarzinom [Prognostic relevance of amplifications of the
oncogenes c-erb B-2 and c-myc in breast cancer]. Lab med
1994, 18:255.
18. Brandt B, Vogt U, Schlotter CM, Jackisch C, Werkmeister R,
Thomas M, von Eiff M, Bosse U, Assmann G, Zänker KS: Prog-
nostic relevance of aberrations in the erbB oncogenes from
breast, ovarian, oral and lung cancers: double-differential
polymerase chain reaction (ddPCR) for clinical diagnosis.
Gene 1995, 159:35-42.
19. Clark GM, McGuire WL: Follow-up study of HER-2/neu ampli-
fication in primary breast cancer. Cancer Res 1991, 51:944-
948.
20. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soder-
borgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed
R,  et al.:  Prognostic importance of c-erb B-2 expression in
breast cancer. International (Ludwig) Breast Cancer Study
Group. J Clin Oncol 1992, 10:1049-1056.
21. Henry JA, Hennessy C, Levett DL, Lennard TWJ, Westley BR,
May FEB: int-2 amplification in breast cancer: Association with
decreased survival and relationship to amplification of c-erb
B-2 and c-myc. Int J Cancer 1993, 53:774-780.
22. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ:
Association of c-erb B-2 protein over-expression with high
rate of cell proliferation, increased risk of visceral metastasis
and poor long-term survival in breast cancer. Int J Cancer
1991, 49:650-655.
23. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrin-
cione CT, Budman DR, Wood WC, Barcos M, Hernderson IC: c-
erb B-2 expression and response to adjuvant therapy in
women with node-positive breast cancer. N Engl J Med 1994,
330:1260-1266.
Available online http://breast-cancer-research.com/content/5/2/R30
R3524. Ravdin PR, Chamness GC: The c-erb B-2 proto-oncogene as a
prognostic and predictive marker in breast cancer: a para-
digm for the development of other macromolecular markers:
a review. Gene 1995, 159:19-27.
25. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K,
Shepard L, Davidson N, Hayes DF, Clark GM, Martino S, Osborne
CK, Allred DC: Initial report of the SWOPG biological correla-
tive study of c-erb B-2 expression as a predictor of outcome
in a trial comparing adjuvant CAF-T with tamoxifen (T) alone
[meeting abstract]. In Proceedings of the American Society of
Clinical Oncology 34th Annual Meeting, May 16–19, 1998. Los
Angeles, CA:374.
26. Roux-Dosseto M, Romain S, Dussault N, Desideri C, Piana L,
Bonier P, Tubiana N and Martin PM: c-myc gene amplification in
selected node-negative breast cancer patients correlates with
high rate of early relapse. Eur J Cancer 1992, 28:1600-1604.
27. Slamon DJ, Clar G.M, Wong SG, Levin WJ, Ullrich A, McGuire
WL: Human breast cancer: correlation of relapse and survival
with amplification of the Her-2/neu oncogene. Science 1987,
235:177-182.
28. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith
DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-
2/neu proto-oncogene in human breast and ovarian cancer.
Science 1998, 244:707-712.
29. Tsuda H, Hirohashi S, Shimosato Y, Taaka Y, Hirota T, Tsugane S,
Shiraishi M, Toyoshima K, Yamamoto T, Terada M: Immunohisto-
chemical study on overexpression of c-erb B-2 protein in
human breast cancer: its correlation with gene amplification
and long-term survival of patients. Jpn J Cancer Res 1990,
81:327-332.
30. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD,
Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS:
The long term prognostic significance of c-erb B-2 in primary
breast cancer. Br J Cancer 1991, 63:447-450.
31. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL,
Horne CH: Response to mitoxantrone in advanced breast
cancer: correlation with expression of c-erb B2 protein and
glutathione S-transferases. Br J Cancer 1992, 65:271-274.
32. Wright C, Nicholson S, Angus B, Sainbury JR, Farndon J, Cairns
J, Harris AL, Horne CH: Relationship between c-erb B-2 protein
product expression and response to endocrine therapy in
advanced breast cancer. Br J Cancer 1992, 65:118-121.
33. Deming SL, Nass SJ, Dickson RB, Trock BJ: C-myc amplification
in breast cancer: a meta-analysis of its occurrence and prog-
nostic relevance. Br J Cancer 2000, 83:1688-1695.
34. Liao DJ, Dickson RB: C-myc in breast cancer. Endocr Relat
Cancer 2000, 7:143-164.
35. Anonymous: Adjuvant tamoxifen in the management of opera-
ble breast cancer: the Scottish Trial. Report from the Breast
Cancer Trials Committee, Scottish Cancer Trials Office (MRC),
Edinburgh. Lancet 1987, 2:171-175.
36. Bonnadonna G, Valagussa T, Zambetti M: Milan adjuvant trial for
stage I-II breast cancer. In Adjuvant Chemotherapy of Cancer V.
Edited by Slamon SW. Orlando, Florida: Grune and Straton;
1987:211-221.
37. Anonymous: Controlled trial of tamoxifen as single adjuvant
agent in management of early breast cancer. Analysis at six
years by Nolvadex Adjuvant Trial Organisation. Lancet 1985,
1:836-840.
38. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC,
Gilchrist KW, Cooper MR, Falkson G: Efficacy of adjuvant
chemotherapy for node-negative breast cancer. An Intergroup
Study. N Engl J Med 1989, 320:485-490.
39. Bloom HJG, Richardson WW: Histologic grading and progno-
sis in breast cancer. A study of 1409 cases which 359 have
been followed for 15 years. Br J Cancer 1957, 11:359.
40. Brand B, Vogt U, Harms F, Bosse U, Zänker KS, Assmann G:
Double-differential PCR for gene dosage estimation of erb B
oncogenes in benign and cancer tissues and comparison to
cellular DNA content. Gene 1995, 159:29-34.
41. Wassmann K: Prognostische Bedeutung DNA-Image-
zytometrischer Parameter für das primäre Mammakarzinom
[Prognostic significance of image cytometric DNA parameters
for primary breast cancer]. Dissertation: University of Muenster,
Muenster, Germany; 1999.
42. Cox DR: Regression models and life tables (with discussion).
J Royal Stat Soc 1972, 34:187-220.
43. Vogt U, Bielawski K, Schlotter CM, Bosse U, Falkiewicz B, Podha-
jska AJ: Amplification of erb B-4 oncogene occurs less fre-
quently than that of erb B-2 in primary human breast cancer.
Gene 1998, 223:375-380.
44. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL: Mecha-
nisms of growth arrest by c-myc antisense oligonucleotides in
MCF-7 breast cancer cells: implications for the antiprolifera-
tive effects of antiestrogens. Cancer Res 2002, 62:3126-3131.
45. Sklar MD, Prochownik EV: Modulation of cis-platinum resis-
tance in Friend erythroleukemia cells by c-myc. Cancer Res
1991, 51:2118-2123.
46. Hynes NE, Lane HA: Myc and mammary cancer: Myc is a down-
stream effector of the ErbB2 receptor tyrosine kinase. J
Mammary Gland Biol Neoplasia 2001, 6:141-150.
47. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H,
Klijn JGM: Urokinase-type plasminogen activator and its
inhibitor PAI-1 predictor of poor response to tamoxifen
therapy in recurrent breast cancer. J Natl Cancer Inst 1995, 87:
751-756.
48. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W,
Ulm K, Jänicke F, Hofler H, Graeff H, Schmitt M: Prognostic
impact of tumor biological factors on survival in node-nega-
tive breast cancer. Anticancer Res 1998, 18:2187-2197.
49. Jänicke F, Schmitt M, Pacte L: Urokinase (uPA) and its inhibitor
PAI-1 are strong independent prognostic factors in node-neg-
ative breast cancer. Breast Cancer Res Treat 1992,  24:195-
208.
Correspondence
Claus M Schlotter, Frauenklinik Klinikum Ibbenbueren, 49477 Ibben-
bueren, Germany. Tel: +49 5451 523036; fax: +49 5451 525054; 
e-mail: C.Schlotter@Klinikum-Ibbenbueren.de.
Breast Cancer Research    Vol 5 No 2 Schlotter et al.
R36